Report

November 12

Join us at the American College of Toxicology (ACT) 41st Annual Meeting

Broughton Nicotine Services, Director of Product Safety and Compliance, Yvonne Wilding and Principal Scientist, Louise Neilson will be in attendance and presenting at ACT 2020.

Broughton Nicotine Services to attend the American College of Toxicology (ACT) 41st Annual Meeting.

Scientific Virtual Forum

ACT is a seven-day event for professional scientists representing the pharmaceutical and biotech industries, regulatory agencies, contract research organizations, academia, and consulting firms.

Yvonne Wilding, Director of Product Safety and Compliance and Louise Neilson, Principal Toxicologist at Broughton Nicotine Services will be presenting the scientific poster, ‘A Novel Secure Software Platform Developed to Conduct Risk Assessments of ENDS’- a unique tool designed to complete rapid toxicological hazard screens and risk assessments on Monday, November 16, 2020 | 5:00 PM–6:30 PM EST.

The 41st virtual Annual Meeting takes place from November 12-19, 2020 and will include a wide-ranging scientific program, plenary speakers, poster session, exhibition hall, and offer the opportunity for professional networking.

Toxicological and Regulatory Support

If you would like to discuss what’s happening in the industry and to find out how Broughton Nicotine Services can help clients in meeting their Toxicological and Regulatory obligations, we would be delighted to speak to you.

P.S Don't forget to join the Toxhunt at ACT Expo Live! - simply collect the required points to be entered into a prize draw, view the schedule highlights here.

ACT Virtual logo (002)

Can we help you?

Broughton Nicotine Services have deep CRO capabilities and an experienced team of scientific and regulatory professionals to manage full service global regulatory projects. Our knowledge of global regulatory pathways offers significant insights that can be incorporated into your project plans. Our mission is to accelerate safer nicotine-delivery products to market; advancing a smoke-free future.

Book a meeting with us today to discuss your requirements.

New call-to-action

 

About the Author

Yvonne Wilding is the Director of Product Safety and Compliance. She has over 10 years of broad regulatory toxicology experience and 20 years of pharmaceutical drug development Research & Development leadership. She has been responsible for numerous MAA and NDA submissions, for both small molecules and biologics and has experience stretching from early candidate selection through life cycle management of new medicines. Her toxicology experience was gained with GlaxoSmithKline's (GSK) large portfolio of respiratory products in a specialized inhalation toxicology department. Yvonne began her career as a regulatory toxicologist for GSK responsible for designing the strategic drug safety evaluation programs to satisfy all global markets using both in-vivo and in-vitro approaches; for operational delivery both with an in-house team and with Contract Research Organisations (CRO). This involved working closely with clinical teams and key opinion leaders to ensure patient safety at each stage of development. She has extensive experience of interacting with regulatory agencies. Following on from Toxicology, Yvonne was responsible for managing and leading drug development programs encompassing all functional disciplines to ensure delivery of successful marketing applications and to maximise the commercial opportunity for each product. Yvonne’s clinical experience encompasses clinical program strategy, study management, clinical portfolio management and pharmacovigilance. Most recently, Yvonne worked with AstraZeneca in the Precision Medicine department to develop new diagnostic tests and submit PMA applications for companion diagnostics devices evaluating genetic biomarkers of disease susceptibility in collaboration with major diagnostic companies.